Acadia Expects Broad Nuplazid Reimbursement; Pricing Soon

Acadia Pharmaceuticals Inc. has not yet priced its newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), but anticipates it will be covered by a vast majority of payers. The PDP approval also sets the stage for expanding Nuplazid's use into other indications, including Alzheimer's disease psychosis and agitation.